Study capecitabine plus niraparib for HER2-negative breast cancer
Part of Cancer, Skin clinical trials.
This Phase 1b/2 trial tests how safe and how well capecitabine combined with niraparib works for people with HER2-negative, hormone-resistant advanced breast cancer. It may help by slowing tumor growth after standard chemotherapy options have been tried.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older.
- Your breast cancer is advanced (locally advanced or metastatic) and HER2-negative on lab testing.
- Your cancer is hormone-resistant (not responding to hormone therapy, as defined by the study).
- Your cancer has grown after treatment with taxanes and anthracycline chemotherapy (unless you couldn’t take them).
- You can swallow the study pills and you have enough recent biopsy/tumor tissue for testing.
- Your heart, blood counts, liver, kidneys, and electrolytes meet study lab limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether adding a chemotherapy medicine called capecitabine (taken in smaller, regular doses) to the standard after-surgery (adjuvant) treatment can lower the chance of cancer coming back in people with early-stage, high-risk HER2-positive breast cancer. It targets patients who still had cancer left after earlier treatment or who had higher-risk tumor features.
This trial tests if adding a chemotherapy drug called capecitabine to the combination of dalpiciclib and hormone therapy works better than dalpiciclib and hormone therapy alone for advanced breast cancer that is hormone receptor-positive and HER2-negative. It is for people who have not had these treatments before.
This study tests whether neratinib plus capecitabine can slow or shrink breast cancer that has spread to the brain. It is for people whose cancer shows an “overactive HER2 signal” on a specific tumor test, even though their cancer is labeled HER2-negative.
This Phase 3 study tests whether adding capecitabine (a chemotherapy pill) after breast cancer surgery can lower the chance the cancer comes back. It targets people with hormone-receptor–positive and HER2-negative breast cancer who are considered “high risk.”
This trial tests a new drug combination (PCS6422 plus capecitabine) for people with advanced or metastatic breast cancer that has not responded to other treatments. The goal is to see if adding PCS6422 can make the chemotherapy work better.
This trial studies whether a low-dose “metronomic” chemotherapy medicine (capecitabine) added to standard hormone therapy can reduce breast cancer coming back. It is for people with hormone-receptor–positive, HER2-negative breast cancer after surgery and chemo.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.